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Highlights  
x We addressed the question of how generalisable evidence for policy making is across health systems by 
using a case study of two similar copayment policies in two different health systems and assessing the 
impact of each policy on adherence.  
x Two similar copayment policies, in apparently similar health systems, did not invoke similar responses 
in adherence to medications. Nuanced differences between the health systems and the patients within 
them may affect differences in impact of policies.  
x Before applying evidence from one health system to the another health system, critical questions of the 
local applicability of the evidence are key to maximising LWV¶XWLOLW\ 
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Abstract 
Introduction of copayments for prescriptions may increase morbidity and mortality. 
Relevant data can inform policy to minimize such unintended effects. We explored the 
generalisability of evidence for copayments by comparing two international polices, one in 
Massachusetts and one in Ireland, to assess whether effects on medication adherence were 
comparable. We used national prescription data for public health insurance programmes in 
Ireland and Medicaid data in the U.S. New users of oral anti-hypertensive, anti-
hyperlipidaemic and diabetic drugs were included (total n= 14,259 in U.S. and n= 43,843 in 
Ireland). We examined changes in adherence in intervention and comparator groups in each 
setting using segmented linear regression with generalised estimating equations. 
In Massachusetts, a gradual decrease in adherence to anti-hypertensive medications of 
-1% per month following the policy occurred. In contrast, the response in Ireland was 
confined to a -2.9% decrease in adherence immediately following the policy, with no further 
decrease over the 8 month follow-up. Reductions in adherence to oral diabetes drugs were 
larger in the U.S. group in comparison to the Irish group. No difference in adherence changes 
between the two settings for anti-hyperlipidaemic drugs occurred. 
Evidence on cost-VKDULQJIRUSUHVFULSWLRQPHGLFLQHVLVQRWµRQHVL]HILWVDOO¶Time 
since policy implementation and structural differences between health systems may influence 
the differential impact of copayment policies in international settings. 
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Introduction 
Health policy interventions such as copayments for prescription drugs aim to control third 
party payer costs. Despite their rational underpinning, a large body of research has 
accumulated over the past four decades detailing the negative impact of prescription 
copayments on prescription drug use and subsequent health outcomes. [1-3]  Most studies 
have found that as the price of the copayment increases, patients reduce their adherence to 
essential life-prolonging drugs that are used in the treatment of chronic disease.[1, 4, 5] 
Copayments for prescription drugs are therefore directly and indirectly associated with 
increased morbidity, mortality and increased health care costs. [3, 6-8]  
 
While the results of previous research on copayments are mostly consistent, the majority of 
studies included in existing systematic reviews have been conducted in the U.S. and Canada. 
[1, 2, 5, 9-11]  For example, all studies included in a review by Gibson et al. were from the 
U.S. or Canada, 54 out 65 studies in a review by Goldman et al. were from North America or 
Canada and so were 18 out of the 21 studies in a Cochrane review on the same topic.[1, 2, 9]  
The limited geographic diversity of the available evidence raises questions about the 
generalisability of results to European health care systems with dissimilar financing, 
organisation and delivery of pharmaceutical care. [12] Given that the development of 
evidence-based policy is contingent upon the availability of valid, reliable evidence pertinent 
to the health system of interest, this issue of uncertain generalisability may hinder 
international policymakers seeking to design prescription drug cost-sharing policies in their 
unique regional settings. [13, 14] For example, when policymakers in countries outside of the 
U.S. and Canada are planning their own prescription copayment policies, they will turn to the 
extant body of systematic reviews and primary research for guidance on the effectiveness of 
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these policies. The challenge they face in this task is assessing how this evidence applies to 
their own local setting. [13, 15] 
 
Cross country comparisons of drug adherence related to cost have been carried out in the 
past. [16, 17] However, these studies were not focused on analysing the impact of a policy 
intervention, rather they reported on prevalence of existing self-reported non-adherence. 
Thus, these results are not useful in providing context for developing copayment policies 
[18], or in anticipating potential patient behaviours resulting from such policies.  
  
To formally address this question of potential international heterogeneity, we designed a case 
study to compare the effects of similar changes in prescription copayment policies, one in 
Massachusetts and one in Ireland, on subsequent adherence. By comparing analogous policy 
changes, we assessed whether changes in adherence behaviours, in response to 
pharmaceutical policy intervention, were broadly generalisable across these two health 
systems. We discuss our findings using the framework suggested by Lavis et al. to 
demonstrate how international evidence should typically be assessed for local 
applicability.[13]  
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Methods 
 
Ethics 
Ethical approval was granted by the Clinical Research Committee of the Cork Teaching 
Hospitals, Ireland and the Institutional Review Board at BrighDP DQG :RPHQ¶V +RVSLWDO
Boston, MA, USA. 
 
The General Medical Services scheme and Medicaid 
The General Medical Services (GMS) scheme is the national tax-funded public primary care 
insurance program in Ireland for people on low incomes and people DJHG70yrs. It provided 
hospital services and primary health care, including General Practitioner visits and 
prescription drugs, to approximately 40% of the population (1.85 million people) in 2013. 
[19] In the U.S., Medicaid is the main public health insurance for low-income parents and 
children, caregivers, pregnant women, disabled adults and low income seniors. [20] In 2011, 
Medicaid provided healthcare for 41 million people across the U.S. including 864,500 people 
in Massachusetts (~13%) and 1.6 million people in Pennsylvania (~13%).[21] 
Policy interventions 
In January 2013, individuals on the GMS scheme were required to pay a ¼ copayment 
per prescription dispensed, DQLQFUHDVHRI¼1 from the previous charge of 50c.  Beginning 
January 2003, Medicaid beneficiaries in Massachusetts were exposed to an increase in their 
copayment, from 50c/prescription to $2/prescription.   
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Patient Populations and Data Sources 
The GMS population comprised the Irish intervention group. The comparator group included 
patients in the publicly funded Long Term Illness (LTI) scheme, because there was no policy 
change on this scheme throughout the study period.  LTI coverage provides free prescriptions 
only and is provided to approximately 60,000 individuals who have been diagnosed with one 
of 16 chronic conditions e.g., diabetes or epilepsy, regardless of their income. [22] If an 
individual has a long term illness, but is also low-income, he/she will qualify for the GMS.  
Person level pharmacy claims data for the GMS and LTI schemes were retrieved from the 
Health Service Executive Primary Care Reimbursement Services (HSE-PCRS) national 
database years 2012-2013. 
 
To provide a global comparison, we used person level prescription data from Massachusetts 
and Pennsylvania Medicaid beneficiaries in the U.S. Medicaid Analytic Extract database 
(MAX), 2002-2004. Pennsylvania Medicaid beneficiaries served as a comparator group for 
this policy change because the copayment in this state remained static ($1/item) throughout 
the study period. Both MAX and PCRS databases have been shown to accurately reflect 
medication use. [23, 24]  
 
Eligible patients were 21-65 years and had continuous eligibility on their respective insurance 
schemes for the study period.  
 
Study Design  
We employed a repeated measures retrospective study. We included new users (no drug 
claim in that medication group in the previous 6 months) of an oral drug for hypertension, 
hyperlipidaemia and/or diabetes in the 6 months prior to policy initiation.[25, 26]  Follow up 
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ran from cohort entry until 8 months after policy implementation (Supplementary 
Information 1). New users of chronic disease drugs follow a well-defined pattern of 
adherence, with typically 50% of new users remaining adherent 6 months post initiation.[27-
29] Our study design allowed new user adherence patterns to occur as expected, but allowed 
analysis of the additional difference in adherence that occurred in response to policy changes.  
Covariates 
We adjusted our estimates of adherence for age and sex. The study design was advantageous 
in that it eliminated confounding by time-invariant variables such as socio-economic 
status.[30]  
Study endpoints 
The outcome was adherence to an oral anti-hypertensive, anti-hyperlipidaemic or diabetic 
drugs, measured monthly based on the Proportion of Days Covered (PDC) method.[27] The 
PDC is typically constructed using two variablesGD\V¶VXSSO\DQGGLVSHQVLQJGDWHBecause 
DGD\V¶VXSSO\YDULDEOHLVQRWUHFRUGHGLQWKH,ULVKGDWD, a GD\V¶VXSSO\ variable was created 
using the number of World Health Organisation (WHO) Daily Defined Doses (DDDs).[31] 
7KHPHWKRGRIFDOFXODWLQJDGD\V¶VXSSO\YDULDEOHXVLQJWKH'''DQGLWVFRQFRUGDQFHZLWK
WKHFRQYHQWLRQDOGD\V¶VXSSO\YDULDEOHLVRXWOLQHGLQRXUSUHYious work. [32] 
Monthly PDCs were calculated for each patient, running consecutively from cohort entry to 
the end of follow up for each individual. If a dispensing occurred before the previous 
dispensing ran out, the new dispensing was assumed to begin the day after the end of the 
prior dispensing and the diary was adjusted accordingly. The PDC was truncated at 1.  If an 
individual was taking more than one drug within a medication class, the number of days that 
a patient had at least one of their drugs was calculated.[33] Switching drugs within a 
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medication class was permitted. In the PCRS data, drugs were identified by WHO 
Anatomical Therapeutic Class grouping (level 3). In Medicaid, National Drug Codes were 
used.  
 
Statistical analysis 
A segmented generalised linear regression model for each country was used to detect changes 
in adherence that occurred after policy implementation. The models included a constant, a 
baseline slope term and terms estimating changes in the level (immediate change in 
adherence) and changes in slope (changes in adherence in the months following the policy). 
[34] [35]  An indicator was included to differentiate between the intervention and the 
comparator group in each country. Policy effects were included in the model as interaction 
terms between exposure group and the policy-specific intercept and slope terms. A one month 
lag period was incorporated to allow the impact of the policy change to take effect, 
acknowledging that most prescriptions are filled every 30 days. We adjusted for correlations 
between repeated measures using generalised estimating equations with a gaussian family, an 
identity link and an autoregressive covariance structure.[36]  
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Results 
The gender breakdown in the GMS and Medicaid groups was reasonably similar; however, 
the LTI population had an approximate ratio of 30:70 female to male. Age was broadly 
comparable between the LTI (52.2yrs) and GMS (49.9yrs) populations, but the Medicaid 
population was slightly younger, with an average age of 47.2yrs in Massachusetts and 47.6yrs 
in Pennsylvania (Table 1). 
*Insert Table 1 here* 
Anti-hypertensive drugs 
Controlling for baseline trends, and relative to the U.S. comparator group, a small, but 
insignificant intercept change indicated no real change in adherence (-0.5%, 95% CI -2.4 to 
1.0) to anti-hypertensive drugs in the Massachusetts Medicaid group immediately after the 
policy was initiated. In contrast, a significant change in slope (-1.1%, 95% CI -1.9 to -0.4) 
indicated that adherence fell in the months following the policy change (Table 2). 
In the Irish GMS group, a significant change in intercept was observed, indicating a 2.9% 
(95% CI -4.2 to -1.6) reduction in adherence to anti-hypertensive drugs relative to the 
comparator LTI group (Table 2).   However, in the months following the policy a positive 
change in slope for the GMS group relative to the LTI group indicated that adherence to anti-
hypertensive drugs did not decline any further in the months following the policy change 
(Table 2).  See Supplementary Information 2 for graphical trends and Supplementary 
Information 3 for demonstration of how a positive change in a previously negative slope 
results in a more gently declining slope. 
Comparing the Massachusetts and Irish policy changes, a 2.4% immediate decrease (intercept 
change) in adherence to anti-hypertensive drugs occurred in Ireland relative to Massachusetts. 
(Table 2 and Figure 1).  In the months following the policy (slope changes), changes in 
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adherence in Ireland appeared to stabilise whereas adherence further declined in 
Massachusetts (Table 2).  
*Insert Table 2 here* 
*Insert Figure 1 here*   
Anti-hyperlipidaemic drugs 
For anti-hyperlipidaemic drugs, both intercept and slope changes were no different between 
the Irish and Massachusetts populations, after baseline trends and comparator groups were 
taken into account (Table 2 and Figure 1). In both settings intercept changes were negligible 
and insignificant suggesting that the policy interventions had no impact on adherence in the 
immediate aftermath. Slope changes were positive, suggesting no long term ramifications on 
adherence to anti-hyperlipidaemic drugs in Ireland or in Massachusetts.  
Oral diabetes drugs 
A significant intercept change indicated a reduction in adherence (-3.1%, 95% CI -5.2 to -1.0) 
to oral diabetes drugs in Massachusetts immediately after the policy was initiated, relative to 
the comparator group. A negative change in slope (-1.2%, 95% CI -2.4 to -0.1) indicated that 
the fall in adherence continued in the months following the policy change (Table 2). 
In the Irish GMS group, a negative change in intercept was observed relative to the 
comparator group, although this was not significant (Table 2). Nor was the difference 
between the Irish intervention and comparator groups for slope change significant, indicating 
no sustained decreases in adherence to oral diabetes drugs.   
Comparing the Massachusetts and Irish policy changes, a 1.8% immediate decrease (intercept 
change) in adherence to oral diabetes drugs occurred in Massachusetts relative to Ireland 
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(Table 2 and Figure 1).  In the months following the policy changes (slope changes), further 
declines in adherence occurred in Massachusetts in comparison to Ireland where there was no 
evidence of further declines (Table 2).  
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Discussion 
We conducted a cross country study to examine whether two similar prescription copayment 
policies impacted on adherence differently in a North American setting and in Ireland.  
 
Compared with their Massachusetts Medicaid counterparts, the Irish GMS population had a 
greater immediate decrease in adherence to anti-hypertensive (-2.4%) drugs. 
However, in the months following the copayment policy, adherence in the Irish intervention 
group declined no further, whereas sustained reductions in adherence of ~1% per month were 
observed in the U.S. group. This finding for gradual declines in adherence agrees with the 
findings of prior research on a copayment change in North America on adherence to beta-
blockers.[37] Over the course of the 8 month follow up period in our study, this 1% per 
month reduction would have resulted in a similar absolute reduction in adherence as occurred 
in Ireland in the immediate term. It is difficult to explain why the Irish intervention group had 
an immediate reaction to the policy change, while the Massachusetts group had a slower 
sustained response. Elucidation of the reasons for these differences would augment our 
understanding of international policy changes in the future, and point to concrete 
explanations for lack of generalizability between health systems.  
 
We found both an immediate and sustained reductions in adherence to oral diabetes drugs in 
the Massachusetts group. These reductions in adherence were larger than observed reductions 
for anti-hypertensive or anti-hyperlipidaemic medicines, agreeing with previous research 
which suggests that patients in the North American setting may value cardiovascular drugs 
over their diabetes drugs.[38, 39] In contrast, the policy elicited no significant change in 
adherence to oral diabetic drugs in the Irish setting. This may be attributable in part to the 
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role out of a national clinical care programme for diabetes in Ireland, initiated in 2010, with 
the aim of improving care for people with diabetes.[40]   
   
Our study is an extreme example of how to ask and answer several questions about using 
international evidence to inform local policy making. [13] In most instances, there will not be 
sufficient time or resources to conduct a study like ours. Rather, policymakers should focus 
on the three question framework devised by Lavis et al. which emphasises that the 
transferability and applicability of evidence from one health system to another should be a 
focus for informing policy decisions.[13]. First, consider structural differences in health 
systems. For example, in our study, the Medicaid and GMS populations were broadly similar 
in that they are both government provided insurance programmes for low-income individuals. 
Although we sought out two similarly structured public health insurance schemes to compare 
policy interventions, we most likely did not capture the diverse structural nuances and 
cultural aspects of international health systems. For example, primary care is not generally a 
focus of the U.S. health system, whereas in Ireland health care relies heavily on the primary 
care service.[41] Differences in chronic care policies are also a feature:  for example the 
presence of a national clinical care programme for diabetes in Ireland may have acted as a 
safeguard against decreases in adherence after the introduction of the policy. Second, assess 
whether there are any differences in the perspectives of health system stakeholders. In our 
study, we did this by looking at patient behaviours in response to the policies. We found 
divergent responses to the copayment policy for anti-hypertensive and oral diabetes drugs in 
each setting, indicating potential international differences in values held for certain diseases. 
Or perhaps this may be reflective of structural differences between the systems as discussed 
above. Third, what is the balance between potential benefits and harms of the policy? 
Policymakers might map out conditions that are highly prevalent or problematic in a 
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population before applying a policy that might worsen preventive and treatment campaigns. 
For example, in Ireland, only 52% of those with hypertension DJHG\UVKDYHWKHLr blood 
pressure controlled to target levels, a proportion not dissimilar to 46.5% of the adult 
hypertensive population in the U.S. [42, 43]  Any additional barriers to anti-hypertensive 
medication adherence may further worsen blood pressure control, and subsequently 
associated cardiovascular health outcomes. This is especially true for a population who is 
high risk, by virtue of their current treatment status. Considering /DYLV¶IUDPHZRUN by 
applying the above three questions helps to tease out the particulars of the policy context, 
which extend beyond geography alone to also include political, economic, population values, 
public health and timing influences.[44] 
Our results should be interpreted with some limitations in mind.  Potential confounding 
variables were often not available in both datasets, a common challenge in using international 
datasets. However we adjusted for age and gender; these factors are amongst the strongest 
predictors of adherence and likely serve as proxies, at least in part, for other variables we 
could not measure.[45]  For example, we did not adjust for polypharmacy in our models, 
which might have been informative regarding burden of cost per person, but age is strongly 
correlated with multi-morbidity and the polypharmacy that goes with this.[46] As a control 
group, the LTI population was suboptimal, given that beneficiaries can qualify on the basis of 
disease independent of income. Despite this, the LTI population served as an informative 
comparison group because any extraneous changes in prescribing practices, clinical 
guidelines or health promotion campaigns for each of the three study diseases would have 
been reflected in this population and therefore conditioned out of the estimation of cost-
sharing policy-specific effects.[47] Our case study examined policy effects on a Medicaid 
programme in Massachusetts and on a public health insurance scheme in Ireland, thus the 
study results are relevant only for low-income health insurance settings. Related to this, 
17 
 
because the population in this study ZDVOLPLWHGWRWKRVHDJHG65yrs, the impact of the 
copayment policy is not generalizable to the whole GMS population in Ireland. These results 
can be found elsewhere.[48]  Finally, the policy changes were separated in real time by 
approximately 10 years. However, we believe that the non-contemporaneous nature of the 
interventions had minimal impact because our results resembled decreases in adherence 
observed after a small copayment in a low income population in the 1970s, implying that 
copayments of small monetary value affect adherence independent of time.[49] Last, positive 
intercept changes were observed in some instances in Massachusetts and Pennsylvania. Our 
study was strengthened by using the most appropriate analysis possible to analyse medication 
use after policy change.[34] We also used large scale pharmacy claims data, which confer 
statistical benefits given the numbers of patients included.[50]  
This study is the first attempt WRFRPSDUHGLIIHUHQFHVLQSDWLHQWV¶medication behaviours in 
response to changes in copayment policy in international settings. We found that adherence 
changes were similar for anti-hyperlipidaemic drugs, but divergent responses were observed 
for anti-hypertensive and oral-diabetes drugs. Thus, international populations do not 
necessarily respond in similar ways to the introduction of a copayment policy. Differences 
may be related to: the length of time since policy implementation; nuanced differences at the 
level of the health system, for example the national clinical care programme for diabetes in 
Ireland; and the value that international populations place on drugs for certain diseases. 
Our study has demonstrated how practical questions surrounding the context of the policy can 
be addressed, thus maximising the utility of international evidence for local policy making. 
From our work, the automatic generalisability of evidence for policy from one setting to 
another appears unwise. Further research can improve on our work by including data from 
several copayment policy interventions in various U.S. states, and in Canada also, and 
compare these to Irish and possibly other European interventions. Such a study would shed 
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light on how policies affect globally diverse populations, and would enhance our 
understanding of generalisability of evidence in the policy realm.  
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Figure Legends 
Figure 1: Intercept changes in Irish and U.S. intervention groups relative to respective 
comparator groups after policy 
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Tables 
 
Table 1 Baseline descriptive characteristics of intervention and comparator groups in Ireland and the 
U.S. 
 Mass Penn Difference GMS LTI Difference 
New users of anti-
hypertensive drugs 
n= 5,184 n=2,555  n= 19,199 n= 2,217  
Female n (%) 3,245(62.6) 1,551(60.7) 1.9% 10,548(54.9) 752(33.9) 21.0% 
Mean age yrs (SD) 45·0 (10.5) 45·8 (10.4) -0.8yrs 48.3(11.4) 52.8(9.1) -4.5yrs 
Ethnicity 
White n (%)^ 3,380(65.2) 2,057(80.5) -15.3% - -  
Black n (%) 582(11.2) 327(12.8) -1.6% - -  
Other n (%) 1,222(23.6) 171(6.7) 16.9% - -  
Other drug use at baseline 
Anti-hyperlipidaemic drugs 1,806(34.8) 891(34.9) -0.1% 2019 (10.5) 306(13.8) -3.3% 
Oral hypo-glycaemic drugs 1,115(21.5) 605(23.7) -2.2% 498 (2.6) 433(19.5) -16.9% 
       
New users of anti-
hyperlipidaemic drugs 
n=2,984 n=1,374  n=14,274 n=2,455  
Female n (%) 1,833(61.4) 846(61.6) -0.2% 7,017 (49.2) 824(33.6) 15.6% 
Mean age yrs (SD) 49.1(9.3) 49.2(9.2) -0.1yr 52.2(9.2) 52.7(8.7) -0.5yrs 
Ethnicity 
White n (%)^ 2,116(70.9) 1,195(87.0) -16.1% - -  
Black n (%) 200(6.7) 95(6.9) -0.2% - -  
Other n (%) 668(22.4) 84(6.1) 16.3% - -  
Other drug use at baseline 
Anti-hypertensive drugs 2,413 (71.8) 1,055(76.8) -5% 2895(20.3) 422 (17.2) -3.1% 
Oral hypo-glycaemic drugs 1,026(34.4) 505(36.8) -2.4% 700(4.9) 609 (24.8) -19.9% 
       
New users of oral diabetes 
drugs 
n=1,419 n=743  n=3, 483 n=2,215  
Female n (%) 908(64.0) 459(61.8) 2.2 1,669 (47.9) 810 (36.6) -11.3% 
Mean age yrs (SD) 48.2(10.3) 47.5(9.8) 0.2yr 49.3 (11.4) 51.1 (10.0) -1.8yrs 
Ethnicity 
White n (%)^ 911(64.2) 562(75.6) -11.4% - -  
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Black n (%) 164(11.6) 97(13.1) -1.5% - -  
Other n (%) 344(24.2) 84(11.3) 12.9% - -  
Other drug use at baseline 
Anti-hypertensive use 1,084(76.4) 555(74.7) 1.7% 1001 (28.7) 256 (11.6) 17.1% 
Anti-hyperlipidaemic use 844(59.5) 393(52.9) 6.6% 797 (22.9) 287 (13.0) 9.9% 
Mass: Massachusetts (U.S. intervention group).   Penn: Pennsylvania (U.S. comparator group) 
GMS: General Medical Services scheme (Ireland intervention group). LTI: Long Term Illness scheme (Ireland comparator 
group) 
^data on race not available in Irish dataset 
Notes: Other medication use at baseline was measured at study entry. 
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Table 2 Intercept (immediate) and slope (gradual) changes in country specific intervention and comparator groups 
 Ireland U.S. 
 % adherence 95% CI p-value % adherence 95% CI p-value 
New users of anti-hypertensive drugs 
Intervention intercept change -5.5 -6.0 to -5.1 p<0.0001 2.9 -1.4 to 1.2 p<0.0001 
Comparator intercept change -2.7 -3.8 to -1.5 p<0.0001 3.4 2.2 to 4.6 p<0.0001 
Between group difference in intercept -2.9 (-4.2 to -1.6, p<0.0001) -0.5 (-2.4 to 1.0, p = 0.5139) 
Intervention slope change 3.4 3.2 to 3.6 p<0.0001 6.9 2.9 to 4.1 p<0.0001 
Comparator slope change 1.3 0.9 to 1.7 p<0.0001 8.0 7.4 to 8.6 p<0.0001 
Between group difference in slope 2.1 (1.7 to 2.6, p<0.0001) -1.1 (-1.9 to -0.4, p= 0.0025) 
New users of anti-hyperlipidaemic drugs 
Intervention intercept change -5.0 -5.6 to -4.4 p<0.0001 3.3 1.9 to 4.6 p<0.0001 
Comparator intercept change -4.3 -5.6 to -3.0 p<0.0001 3.5 1.8 to 5.2 p<0.0001 
Between group difference in intercept -0.7 (-2.2 to 0.7, p = 0.3152) -0.3 (-2.4 to 1.9, p= 0.8126) 
Intervention slope change 2.4 2.2 to 2.6 p<0.0001 8.9 8.4 to 9.5 p<0.0001 
Comparator slope change 1.6 1.2 to 2.0 p<0.0001 7.9 7.1 to 8.6 p<0.0001 
Between group difference in slope 0.8 (0.3 to 1.2, p=0.0017) 1.0 (0.2 to 2.0, p = 0.0222) 
New users of oral diabetes drugs 
Intervention intercept change -6.1 -7.2 to -5.0 p<0.0001 -0.1 2.0 to 5.4 p=0.90094 
Comparator intercept change -4.8 -6.1 to -3.5 p<0.0001 3.0 1.4 to 4.5 p=0.00023 
Between group difference in intercept -1.3 (-3.0 to 0.4, p= 0.1291) -3.1 (-5.2 to -1.0, p= 0.00358) 
Intervention slope change -0.4 -0.5 to -0.2 p<0.0001 3.5 8.0 to 9.4 p<0.0001 
Comparator slope change -0.2 -0.4 to -0.04 p=0.0121 4.7 3.7 to 5.7 p<0.0001 
Between group difference in slope -0.2 (-0.4 to 0.03 , p= 0.1147) -1.2 (-2.4 to -0.1, p= 0.03587) 
Intervention group Ireland: General Medical Services (GMS) scheme. Comparator group Ireland: Long Term Illness (LTI) scheme 
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Intervention group U.S.: Medicaid Massachusetts. Comparator group U.S.: Medicaid Pennsylvania 
Graphs demonstrating trends provided in Supplementary Information 2.  
Baseline intercepts and baseline slopes provided in Supplementary Information 4. 
 

